Search Results for: 2017 GLOBAL DRUG DELIVERY FORMULATION
Articles
BIOSIMILAR DEVELOPMENT - Biosimilars: The Process & Quality System Approach to Clinical Applications January 13, 2021
Kaiser Aziz, PhD, addresses biosimilar developments and future innovations with an emphasis placed on quality system approaches to the development and availability of new biosimilar products.
CanSino Biologics & Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine May 20, 2020
CanSino Biologics Inc. and Precision NanoSystems (PNI) recently announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will…
SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: Innovations, Challenges & Solutions May 5, 2020
Contributor Cindy H. Dubin features several leading companies’ innovations in delivery devices as well as how contract parenteral manufacturers are addressing the ever-demanding challenges, issues, and opportunities related to delivering biologics and small molecules.
BIOSIMILAR DEVELOPMENT - Biosimilar Biological Products: Development & Applications March 2, 2020
Kaiser J. Aziz, PhD, provides an in-depth overview of biosimilar products development and the evaluation criteria for FDA approval.
SPECIAL FEATURE - Injection Devices: Wearables, Connectivity & Patient-Centric Designs Empower Self-Administration September 3, 2019
Contributor Cindy H. Dubin highlights the innovation in injection devices – from wearables to connectivity to varied dose administration – that have occurred in the past year.
SMART DEVICES - Add-On Connectivity Facilitates New Generation of Smart Inhalers April 1, 2019
Contributor Cindy H. Dubin reviews how the addition of electronic and connectivity to inhalers may improve patient adherence and, consequently, treatment efficacy.
SPECIAL FEATURE - Excipients: Formulators Want Excipients for Solubility & Beyond April 1, 2019
Contributor Cindy H. Dubin speaks with leading excipient companies to discuss the current role excipients are playing in continuous manufacturing, biopharma formulation, and controlled- and immediate-release delivery.
EXECUTIVE INTERVIEW - SK life science: Challenges of Developing Therapies for Neurological Diseases February 28, 2019
Sebby Borriello, Vice President & Chief Commercial Officer, speaks about the challenges and trends surrounding development of therapies for neurological diseases.
THERAPEUTIC FOCUS - Applying the HIV Treatment Model to Hepatitis B – Can a Cocktail Provide a Cure? October 1, 2018
James Sapirstein, RPh, says in the ongoing search for a cure to hepatitis B, experts now believe that combining different drugs into a single regimen can work together against HBV and will be the most likely way to achieve a cure.
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals July 3, 2018
Catalent, Inc. recently announced it has agreed to acquire Juniper Pharmaceuticals, Inc., including its Nottingham, U.K.-based Juniper Pharma Services division....Biologic Excipients Market Expected to be Valued at $1.7 Billion by End of 2028 July 3, 2018
Future Market Insights (FMI) delivers key insights on the global biologic excipients market in its upcoming report titled Biologic Excipients Market: Global Industry Analysis 2013–2017 and Opportunity Assessment…
Evonik Expands North American Contract Development & Manufacturing Capabilities for Advanced Injectables June 28, 2018
Evonik recently announced a €35 million expansion of its contract development and manufacturing (CDMO) capabilities in North America to meet growing demand for controlled release injectable formulations. The expansion of the U.S. and Canadian facilities, which includes the installation of a new filling line, production facilities and analytical labs, will create more than 50 jobs.
Nutriband Signs LOI to Acquire Carmel Biosciences June 21, 2018
Nutriband Inc. recently announce it has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company...Catalent Announces Organizational Restructuring to Support Customer Demand for Fast, Integrated Biologics Development April 27, 2018
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health...SPECIAL FEATURE - Challenging Molecules Drive Developers to Get More Creative With Excipients April 2, 2018
Contributor Cindy H. Dubin highlights the techniques various excipient manufacturers are using to develop more innovative and effective ingredients to improve the performance of drug molecules.
SPECIAL FEATURE - Injection Devices: Manufacturers Focus on 21st Century Technology While Still Tackling Traditional Challenges March 14, 2018
Contributor Cindy H. Dubin highlights some of the key companies in the injectable delivery market that are focusing on advanced technology as well as the more traditional challenges related to breakage, leaching, and needlestick prevention.
Biohaven Announces Exclusive License Agreement With Catalent February 21, 2018
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") recently announced it has entered into an exclusive worldwide...Rexahn Pharmaceuticals Announces Collaboration With Zhejiang Haichang Biotechnology February 13, 2018
Rexahn Pharmaceuticals, Inc. recently announced it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd....SPECIAL FEATURE - Analytical Testing - Contractors Take on the Challenge of Complex Molecules January 9, 2018
Contributor Cindy H. Dubin highlights some of the analytical testing services that leading contractors offer aimed at the increasing complexities of today’s pharmaceutical pipelines.
EXECUTIVE INTERVIEW - Lonza Pharma & Biotech: Taking on the Next Challenges in Small Molecules November 20, 2017
Gordon Bates, Head of Chemical Division at Lonza Pharma & Biotech, shares his perspective about industry needs and how strategic acquisitions are enhancing Lonza’s position as a development and manufacturing partner of choice.
Outsourcing Drug Development & Production: Technology-Driven Drug Delivery Systems for Small Molecules at Losan Pharma
Due to the increasing demand for drug delivery systems that are able to improve the properties of low soluble, poor permeable, or highly dosed new and existing drug substances, technology-driven CDMOs can offer a wide range of technology platforms to overcome such challenges….
